# A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

> **NCT07408232** · PHASE1,PHASE2 · RECRUITING · sponsor: **Octant, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **DRUG:** Phase 1a: OCT-980 Capsule
- **DRUG:** Phase 1a: Placebo Capsule
- **DRUG:** Phase 1b/2: OCT-980 Tablet

## Key facts

- **NCT ID:** NCT07408232
- **Lead sponsor:** Octant, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-09
- **Primary completion:** 2028-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07408232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07408232, "A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07408232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*